Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?
José Carlos Dos SantosMartin SchäferUlrike Bauder-WüstWencke LehnertKarin LeottaAlfred MorgensternKlaus KopkaUwe HaberkornWalter MierClemens KratochwilPublished in: European journal of nuclear medicine and molecular imaging (2019)
212Pb-CA012 is a promising candidate for PSMA-targeted alpha therapy of prostate cancer. The dosimetry estimate for radiopharmaceuticals decaying with the release of unstable daughter nuclides has some inherent limitations, thus clinical translation should be done cautiously.